FDA approves Mercay's heavy immunotherapy Keytruda to be marketed for treatment of large B-cell lymphoma

PMBCL is an invasive diffuse large B-cell lymphoma that accounts for about 2 to 4 percent of all non-Hodgkin lymphomas, a disease that mainly affects young people and is about 1.7-2 times more likely to be in male patientsrecently, MsMersadon (MSD) announcedFDA(which has approved the launch of its heavy immunotherapy Keytruda for the treatment of large B-cell lymphoma (PMBCL, a non-Hodgkin lymphoma)It is worth mentioning that this is the first anti-PD-1 treatment to treat the disease, and the second indication of Keytruda in the field of malignant blood cancerKeytrudaKeytruda is an immunotherapy that has been approved for a wide range of cancers to treat melanoma, non-small cell lung cancer, and head and neck squamous cell carcinomaKeytruda can selectively block PD-1 in combination with its ligands PD-L1 and PD-L2, activating lymphocytes to kill cancer cells, Mershadon is conducting 750 different clinicaltrial strial
for Keytrudaapproval of pmBCL indications is based on trial data from multi-center, open label, single-arm clinical research KEYNOTE-170Patients receive a fixed dose of 200 mg of Keytruda monodotherapy every three weeks until the disease progresses or becomes unacceptableThe primary endpoint is the Overall Mitigation Rate (ORR), and the key secondary endpoints include The Duration of Remission (DOR),drug(safety and tolerability)results showed that the ORR in the Keytruda treatment group was 45% (24 cases, 95% CI: 32-60), the total remission rate (CRR) was 11%, and the partial remission rate (PRR) was 34%Of the 24 patients who participated in follow-up, the median DOR had not yet reached (range: 1.1-19.2 months) and the median time for objective remission (full or partial) was 2.8 months (range: 2.1-8.5 months)